CORAL GABLES, FL / ACCESSWIRE / December 31,2018 / This year has been a year which has seen significant market volatility, but the healthcare sector has managed to remain above the curve by constantly working to design and implement innovative approaches to medical care for patients suffering from a variety of serious illnesses. As experts and professionals in the field have worked on developing technologies to improvequality of care available for consumers, the healthcare industry, as a whole, has seen tremendous growth. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Axsome Therapeutics Inc (AXSM), Marimed Inc (MRMD), and Marker Therapeutics Inc (MRKR) are 4 healthcare companies worth keeping tabs on as we head into the new year.
Premier Health Group (PHGRF) (PHGI) has come into the limelight this past year as a result of the Company's dedication to investing in the development of innovative, high tech treatment solutions for patients in the primary care space. Over the course of the past thirty days, Premier has seen a period of bullish trading as its shared climbed over 30% this past month.
Recent reports indicate that the Company currently boasts an ecosystem of over 100,000 active patients in their network, with plans in the works to increase those numbers on a global scale.
Earlier this month, Premier Health Group (PHGRF) (PHGI) announced that, in an effort to advance its overarching strategy to cover all major verticals associated with primary care as well as develop innovative approaches that combine human skill-based expertise with emerging technologies, it had signed a binding LOI to acquire all outstanding securities of Cloud Practice Inc.
Dr. EssamHamza, CEO of Premier Health, said: "We are ecstatic at the opportunity to build on ourpatient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online bookingand other premium services with our electronic medical record (EMR) system."
For More Information On Premier Health Group, Click Here
Axsome Therapeutics, Inc (AXSM), one of several clinical-stage biopharmaceutical companies developing novel treatment options for those looking to manage disorders related to the central nervous system, provided investors with their most recent clinical update for its CNS treatment options earlier this month.
In a press release regarding the clinical update, the Company shared that, to date, just under 90% of the target number of subjects for theirtreatment resistant depression trials have demonstrated topline results after participating in STRIDE-1, a multi-center, randomized, double-blind, controlled trial in which subjects with TRD are randomized to treatment with AXS-05 or bupropion.
For More Information On Axsome Therapeutics, Inc, Click Here
With the recent passing of the US Farm Bill, companies like MariMed Inc (MRMD) are prepared to meet the demands of the healthcare industry as more medical professionals become accepting of cannabidiol (CBD) as a form of treatment for their patients. The bill included language which will allow for hemp to be grown on a massive agricultural scale.
In a press release regarding the matter, Charles Finnie, MariMed's Chief Strategy Officer, said:
"Legal hemp has the potential to reshape America's health and wellness landscape," said Charles Finnie, MariMed's Chief Strategy Officer. "CBD will likely become a separate industry from the highly regulated, state-legal cannabis industry that remains illegal at the federal level. Lifting federal restrictions on hemp cultivation, research and distribution will enable advanced medical research, as well as increased agricultural production of pharmaceutical-quality CBD products that avoid the side effects and addiction risks of some pharmaceuticals ."
For More Information on MariMed, Inc, Click Here
Marker Therapeutics, Inc (MRKR), in an effort to maintain a cohesive leadership team determined to take the clinical-stage immuno-oncology company to greater heights, announced the appointment of Anthony Kim as their new Chief Financial Officer back in November.
At the time of the announcement, Peter L. Hoang, Presidentand CEO of Marker, said:
"I have known Tony Kim for almost twenty years and I consider him to be one of the most talented financial professionals I've worked with during that time. I am absolutely delighted to have him join our team at Marker Therapeutics. Tony brings a wealth of knowledge and experience in the life sciences sector, along with strong relationships in the biotech- and healthcare-focused institutional investor community and has been our trusted lead advisor for the last year as we navigated our merger and financing process. As we continue to execute on our strategy, we recognize that the needs of our organization, the number of opportunities available to us, the breadth of our clinical portfolio, and the magnitude of our commitments in the marketplace have all increased dramatically.
For More Information On Marker Therapeutics, Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com